Charles Schwab Investment Management Inc. Buys 5,478 Shares of Repligen Co. (NASDAQ:RGEN)

Charles Schwab Investment Management Inc. raised its stake in Repligen Co. (NASDAQ:RGEN - Free Report) by 1.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 363,379 shares of the biotechnology company's stock after acquiring an additional 5,478 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.65% of Repligen worth $54,078,000 at the end of the most recent reporting period.

Other hedge funds have also recently bought and sold shares of the company. Lazard Asset Management LLC boosted its stake in Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 136 shares during the period. B. Riley Wealth Advisors Inc. increased its position in Repligen by 12.6% during the first quarter. B. Riley Wealth Advisors Inc. now owns 1,450 shares of the biotechnology company's stock worth $267,000 after acquiring an additional 162 shares during the period. Tidal Investments LLC raised its stake in Repligen by 11.6% in the 1st quarter. Tidal Investments LLC now owns 1,421 shares of the biotechnology company's stock worth $261,000 after purchasing an additional 148 shares in the last quarter. Virtu Financial LLC boosted its holdings in Repligen by 29.3% in the 1st quarter. Virtu Financial LLC now owns 1,545 shares of the biotechnology company's stock valued at $284,000 after purchasing an additional 350 shares during the period. Finally, Swedbank AB acquired a new position in shares of Repligen during the 1st quarter worth approximately $5,518,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $205.00 price target on shares of Repligen in a research note on Thursday, September 26th. Benchmark reaffirmed a "hold" rating on shares of Repligen in a research report on Monday, August 5th. StockNews.com upgraded shares of Repligen from a "sell" rating to a "hold" rating in a research note on Friday, November 22nd. Wells Fargo & Company started coverage on shares of Repligen in a report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 price target for the company. Finally, Wolfe Research started coverage on shares of Repligen in a research report on Thursday, November 14th. They set a "peer perform" rating on the stock. Four analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, Repligen currently has an average rating of "Moderate Buy" and a consensus target price of $190.25.

Repligen Trading Up 0.4 %

Shares of NASDAQ:RGEN traded up $0.55 during trading on Friday, hitting $150.54. 225,812 shares of the company were exchanged, compared to its average volume of 700,387. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13. The business's 50 day moving average is $140.98 and its 200-day moving average is $142.65.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.34 by $0.09. The business had revenue of $154.87 million during the quarter, compared to analysts' expectations of $153.34 million. Repligen had a positive return on equity of 3.90% and a negative net margin of 3.36%. The business's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.23 EPS. Sell-side analysts predict that Repligen Co. will post 1.52 EPS for the current year.

Insider Buying and Selling

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company's stock, valued at approximately $20,328,540.80. This represents a 13.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.20% of the stock is owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.